TTFields therapy — PDUFA
Q4 2026
Decision by the U.S. FDA on the PMA application for the use of TTFields therapy for the treatment of brain metastases from NSCLC (Q4 2026).Source filing
NVCR biotech catalysts & pipeline
NOVOCURE LTD · Data as of 2026-09-08
Upcoming catalysts
TTFields therapy — Regulatory decision
Q4 2026
Decision by the U.S. Food and Drug Administration on the premarket approval application for use of TTFields therapy for the treatment of brain metastases from non-small cell lung cancer (Q4 2026).Source filing
TTFields therapy — Conference presentation
Sep 26–Sep 30
Full results from the TRIDENT trial have been accepted for presentation at the American Society for Radiation Oncology 2026 Annual Meeting.Source filing